Interferons are a family of naturally occurring proteins that are produced by eukaryotic cells and mostly show action against viral infections and other biological inducers. There are three major forms of interferons that have been distinguished as alpha, beta, and gamma. The interferon beta drug represents the first class of disease modifying therapies (DMTs) for multiple sclerosis (MS) and also contributed to reseacrhers’ understanding of immunomodulatory mechanisms in MS. The drug is administered through intramuscular or subcutaneous route of administration. There are five types of interferon beta drugs; Avonex, Betaseron, Extavia, Plegridy, and Rebif in the market. The drug is available in different dosage forms such as solution, and kit (lyophilized powder in a single-dose vial for reconstitution).
The global interferon beta drugs market is estimated to be valued at US$  3,795.3 million in 2020 and is expected to exhibit a CAGR of 3.5% during the forecast period (2020-2027).
Get Request For Sample copy: https://www.coherentmarketinsights.com/insight/request-sample/4250
Global Interferon Beta Drugs Market - Drivers
The increasing focus of market player on development of novel interferon beta drugs is another factor driving the growth of the global interferon drugs market. For instance, on July 22nd 2020, Synairgen, a company based in Southampton, UK, announced positive results from a clinical trial of SNG001 in hospitalised COVID-19 patients. SNG001 is an inhaled formulation of interferon beta. According to the study, the risk of developing severe COVID-19 symptoms during the treatment period of 16 days was reduced by 79% in the patients receiving SNG001.
Moreover, the increasing prevalence of the multiple sclerosis is expected to boost the growth of the global interferon beta drugs market. For instance, according to data published Multiple Sclerosis Trust (MST) in 2020, an estimated 2,500,000 people in the world have multiple sclerosis. Research suggests the proportion of women with MS is increasing and that around two to three women have MS. The prevalence of MS varies according to region. According to the MTS, Asia, Africa and America that lie on the equator have low prevalence of MS, while Canada and Scotland have particularly high prevalence.
Global Interferon Beta Drugs Market - Restraints
Interferon beta drugs are most commonly used in the treatment of multiple sclerosis. The condition can also be treated with alternative therapies such as corticosteroids, monoclonal antibodies, antineoplastic agents. Moreover, approval and launch of therapies is expected to hamper demand for interferon beta drugs. For instance, in 2017, the FDA approved Genentech’s Ocrevus (ocrelizumab) a humanized monoclonal antibody targeting B-cells with CD20 molecule. Ocrevus is the only therapy approved for both relapsing and primary progressive forms of multiple sclerosis. Thus, approval for such products is likely to hamper the growth of the global interferon beta drugs marke
Global Interferon Beta Drugs Market - Regional Analysis
On the basis of region, the global interferon beta drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
The Europe interferon beta drugs market is expected to exhibit significant growth during the forecast period owing to presence major players, approval of interferon beta drugs, and the increasing prevalence of the MS in the region. For instance, in 2017, BIOCAD, a biotechnology company in Russia, received approval from the Russian Ministry of Health interferon beta-1a non-originator biological drug, BCD-033. The drug is a non-originator biological of Merck’s multiple sclerosis blockbuster Rebif (interferon beta-1a). Moreover, presence of major players such as Bayar, Novatis, and Merck KGaA in Europe, another factor contributing to growth of the Europe interferon beta drugs market.
TO Get More Access, Purchase Report Here @ https://www.coherentmarketinsights.com/insight/buy-now/4250
Key Players:
Major players operating in the global interferon beta drugs market are Biogen Idec., Merck KGaA, Novartis Pharmaceuticals Corporation, and Bayer.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: [email protected]